Key contacts

Will Corkill

Will Corkill

Simon Wilson

Simon Wilson

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
NSW 2000
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research


Omega-3 plant is all go

Update | Food & Drink | 30/11/2015

SeaDragon (SEA) is a final-stage fish oil processor based in Nelson, New Zealand. Its existing 300 tonne (t) capacity plant produces omega-2 oils for the global dietary supplements market. A new 5,000t omega-3 plant has been commissioned and the first production of omega-3 will begin in late December 2015. A NZ$10m capital raise (completed on 2 October 2015), double H115-on-H116 sales and confirmation that the FY16 EBITDA target of NZ$0.144m should be achieved are positive indicators. We see entry…

St George Mining

Potential for a large-scale nickel discovery

Review | Mining | 27/11/2015


Combination trials gather momentum

Update | Pharmaceutical & Healthcare | 26/11/2015

Viralytics is escalating combination trials of its Cavatak oncolytic virotherapy with immune checkpoint inhibitors (ICI), adding a collaboration with Merck to study IV Cavatak combined with Keytruda in advanced lung and bladder cancers to its portfolio of ongoing trials combining intralesional Cavatak with Keytruda or Yervoy in melanoma patients. Cavatak has the potential to markedly improve the proportion of patients who respond to ICI therapy and we expect it to continue to attract attention from…

Sealegs Corporation

Sea change

Update | Engineering | 24/11/2015

Sealegs (SLG) reported better than expected H1 results, driven by tighter cost management and increased sales from the higher-margin amphibious enablement systems (AES) and B2B sales to hull manufacturers. Since reappointing founder David McKee Wright as CEO in November 2014, the Auckland-based company has focused on developing a licensing strategy for its amphibious enablement systems, which we see as a significant game-changer for Sealegs. The company has recently passed a number of milestones…

Tourism Holdings

FY16 on track

Update | Travel & Leisure | 24/11/2015

At its Annual Meeting Tourism Holdings (THL) provided guidance for FY16 of NZ$37m EBIT and NZ$22m NPAT. This is an expected annual increase in NPAT of 10%. THL reported that the tourism markets in its key markets of New Zealand and Australia remain strong and that ongoing focus on cost reduction, improved efficiency and innovative ways to reduce capital costs are expected to drive ROCE. The company expects to achieve its long-term average ROCE of 14% in FY16. Our FY16 EBIT forecasts EBIT are unchanged.…


Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports